Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19

di Trojaniello, C., Vitale, M.G., Ascierto, P.A.
Pubblicato in Ann Oncol (2021)

How we treat locoregional melanoma

di Troiani, T., De Falco, V., Napolitano, S., Trojaniello, C., Ascierto, P.A.
Pubblicato in ESMO Open (2021)

Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications

di Pisano, M., Baldinu, P., Sini, M. C., Ascierto, P. A., Tanda, F., Palmieri, G.
Pubblicazione 2008

Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases

di Palmieri, G, Cossu, A, Ascierto, P A, Botti, G, Strazzullo, M, Lissia, A, Colombino, M, Casula, M, Floris, C, Tanda, F, Pirastu, M, Castello, G
Pubblicazione 2000

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

di Galon, J., Fox, B. A., Bifulco, C. B., Masucci, G., Rau, T., Botti, G., Marincola, F. M., Ciliberto, G., Pages, F., Ascierto, P. A., Capone, M.
Pubblicato in J Transl Med (2016)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma

di De Divitiis, C., von Arx, C., Grimaldi, A. M., Cicala, D., Tatangelo, F., Arcella, A., Romano, G. M., Simeone, E., Iaffaioli, R. V., Ascierto, P. A., Tafuto, S.
Pubblicato in J Transl Med (2016)

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

di Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., Savage, K. J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H. B., Waxman, I. M., Abernethy, A. P.
Pubblicato in Ann Oncol (2016)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

di Chiarion-Sileni, V, Pigozzo, J, Ascierto, P A, Simeone, E, Maio, M, Calabrò, L, Marchetti, P, De Galitiis, F, Testori, A, Ferrucci, P F, Queirolo, P, Spagnolo, F, Quaglino, P, Carnevale Schianca, F, Mandalà, M, Di Guardo, L, Del Vecchio, M
Pubblicazione 2014

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

di Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P C, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A, McArthur, G A
Pubblicato in Ann Oncol (2017)

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

di Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J.-J., Murawa, P., Dreno, B., Ross, M., Weber, J., Hauschild, A., Rutkowski, P., Testori, A., Levchenko, E., Enk, A., Misery, L., Vanden Abeele, C., Vojtek, I., Peeters, O., Brichard, V. G., Therasse, P.
Pubblicato in Ann Oncol (2016)

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

di Marabelle, A, Andtbacka, R, Harrington, K, Melero, I, Leidner, R, de Baere, T, Robert, C, Ascierto, P A, Baurain, J -F, Imperiale, M, Rahimian, S, Tersago, D, Klumper, E, Hendriks, M, Kumar, R, Stern, M, Öhrling, K, Massacesi, C, Tchakov, I, Tse, A, Douillard, J -Y, Tabernero, J, Haanen, J, Brody, J
Pubblicato in Ann Oncol (2018)

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

di Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F
Pubblicato in ESMO Open (2016)

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

di Eggermont, A.M.M., Chiario-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J.D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P.A., Richards, J.M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J.S., Maio, M., Bastholt, L., Mortier, L., Thomas, L., Tahir, S., Hauschild, A., Hassel, J.C., Hodi, F.S., Taitt, C., de Pril, V., de Schaetzen, G., Suciu, S., Testori, A.
Pubblicato in N Engl J Med (2016)

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

di Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M.S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P.A., Long, G.V., Cebon, J., Sosman, J., Postow, M.A., Callahan, M.K., Walker, D., Rollin, L., Bhore, R., Hodi, F.S., Larkin, J.
Pubblicato in N Engl J Med (2017)